Sanofi Confident In Beyfortus Achieving Blockbuster Status In 2024

Foresees Strength Versus Future RSV Antibody Competitor

 
• By Mandy Jackson
  
Sanofi logo at a skyscraper in Warsaw, Poland
Beyfortus and Dupixent bookended Sanofi's sales in terms of lowest and highest sellers in Q2 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip